Bolt Biotherapeutics, Inc. BOLT 深 沪
交易中 11-05 10:22:35 美东时间
6.285
-0.255
-3.90%
华盛通- 最 高6.39
- 今 开6.39
- 成交量 1.75万股
- 最 低 6.18
- 昨 收 6.54
- 总市值 1481.43万
- 52周最高 7.78
- 市盈率 静 --
- 换手率 0.74%
- 52周最低 3.10
- 委 比 0.00%
- 总股本 235.71万
- 历史最高 861.40
- 量 比 1.85
- 振 幅 3.21%
- 历史最低 3.10
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bolt Biotherapeutics to Participate in Upcoming Conferences
Bolt Biotherapeutics announced its participation in two upcoming investor conferences in November 2026. Sheila Gujrathi, Bolt's Chief Strategy Officer and former CEO of Prana Therapies, will present at the Stifel 2026 Healthcare Conference on November 10 and attend the Jefferies Global Healthcare Conference in London from November 16–19. Bolt acquired Prana Therapies in October 2026 through a stock-for-stock reverse merger and a $120 million priv...
11-03 13:00
Bolt Biotherapeutics Secures $120M Private Placement, With Potential Additional $60M From Warrant Exercise To Fund Operations Into 2028
Concurrent with the acquisition, Bolt entered into a definitive agreement for a private placement financing to raise $120 million in gross proceeds, for the purchase of 13,995.311 shares of Series D non-voting convertible preferred stock (or 13,995,311 shares of Bolt common stock on an as-converted-...
10-23 21:19
Bolt Biotherapeutics Acquires Prana Therapies In Sign-And-Close Reverse Merger, Shifts Focus To Multispecific Antibody Pipeline; Prana Holders to Own 51.7% of Combined Company, Backed by Up To $180M Financing
Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform PRA-216 is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development for asthma, COPD, and atopic dermatitis, wit...
10-23 21:17
Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
Bolt Biotherapeutics acquired Prana Therapies, gaining access to its INSPIRE platform for developing next-generation multispecific antibodies. The deal includes a $120 million private placement with potential for an additional $60 million, funding operations into 2028. PRA-216, a Phase 2 bispecific antibody targeting asthma, COPD, and atopic dermatitis, is the lead product. Prana's co-founder, Sheila Gujrathi, joins Bolt's executive team. The tra...
10-23 13:08
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Wes Burwell has joined Nurix Therapeutics as Chief Human Resources Officer, bringing over 20 years of leadership experience in scaling organizations through clinical development and commercialization. He will lead Nurix's human resources team as the company advances its late-stage clinical pipeline and prepares for commercialization. Burwell previously served as vice president of human resources at Bolt Biotherapeutics and held senior HR roles at...
08-20 11:00
Bolt Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Bolt Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-12 23:17
Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per share from the same period last year. The company reported quarterly sales of $5.000 t...
08-12 04:20
美股大行评级 | Susquehanna上调美光目标价从600美元升至1750美元；戴尔、MongoDB、网泰信息存储、Nextpower、Okta等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从7美元升至7.5美元；Susquehanna：维持美光科技"积极"评级，目标价从600美元升至1750美元
06-01 14:11
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
05-28 18:39
